1 / 33

Interstitial Lung Disease -associations with autoantibodies

Interstitial Lung Disease -associations with autoantibodies. Dr Felix Woodhead Locum Respiratory Physician UHCW 5 October 2010. History of Fibrosing Alveolitis. Corrigan 1838: “on cirrhosis of the lung” Hamman-Rich syndrome 1935 Scadding 1964 – Fibrosing alveolitis

Télécharger la présentation

Interstitial Lung Disease -associations with autoantibodies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Interstitial Lung Disease-associations with autoantibodies Dr Felix Woodhead Locum Respiratory Physician UHCW 5 October 2010

  2. History of Fibrosing Alveolitis • Corrigan 1838: “on cirrhosis of the lung” • Hamman-Rich syndrome 1935 • Scadding 1964 – Fibrosing alveolitis • Idiopathic pulmonary fibrosis in USA • Averrill Liebow – pathology 1950s

  3. Associations of ILD • Inorganic dusts (pneumoconiosis) • Organic dusts (Hypersensitivity Pneumonitis) • Drugs • Rheumatological disease • Idiopathic

  4. Cryptogenic Fibrosing Alveolitis Bibasal Crackles Restrictive Spirometry or isolated low TLco Basally-predominant fibrosis on CXR Absence of pneumoconiosis, EAA or known connective tissue disease RA, SLE SSc, PM/DM

  5. Patient 1

  6. Patient 1 – Histopathology UIP

  7. Patient 1 –Idiopathic Pulmonary Fibrosis (IPF) • Not interchangeable term for Idiopathic Interstitial Pneumonia • ?most common IIP • Relatively poor prognosis • Median survival 2 ½ years • Histology • Usual Interstitial Pneumonitis (UIP) when biopsied • Temporal and Spatial heterogeneity, not uniform • Radiology • Typical features: basal, peripheral honeycombing, little ground glass • May have any appearance • Typical features – don’t need to biopsy, atypical – biopsy helpful

  8. Patient 2

  9. Patient 1

  10. Patient 2 – Respiratory Bronchiolitis

  11. Smoking-related IIP • Respiratory Bronchiolitis • Histological appearance in ‘healthy smokers’ • Pigmented macrophages in terminal bronchioles • Clinical condition RB associated ILD (RBILD) • RBILD radiology similar to Hypersensitivity Pneumonitis (EAA) • BAL not lymphocytic • DIP • ‘Desquamative’ due to erroneous belief cells shed into alveoli • Diffuse collection of pigmented macrophages throughout alveoli • Radiologically typified by diffuse GGO • ?smoking related NSIP, Fibrosis and emphysema

  12. The _IPs: Interstitial Pneumonias • UIP – Usual, the most common, IPF • NSIP – non-specific • AIP – acute, Hamman-Rich, ARDS • DIP – desquamative, ↑macrophages, smoking (RBILD – respiratory bronchiolitis – associated ILD) • LIP – lymphocytic, HIV and connective tissue disease

  13. 2002 ATS/ERS guidelines for Idiopathic Interstitial Pneumonia Am J Respir Crit Care Med 2002 Nicholson et al Am J Respir Crit Care Med 2000

  14. Patient 3

  15. Cryptogenic Fibrosing Alveolitis Bibasal Crackles Restrictive Spirometry or isolated low TLco Basally-predominant fibrosis on CXR Absence of pneumoconiosis, EAA or known connective tissue disease RA, SLE SSc, PM/DM

  16. Systemic Sclerosis • Scleroderma – skin thickening above MCPs • Sclerodactyly – skin thickening of fingers • Digital pitting scars • Bibasal pulmonary fibrosis • Major criterion or two or more minor criteria • Limited cutaneous (lcSSc) vs diffuse cutaneous (dcSSc) • lcSSc ‘CREST’ syndrome

  17. Interstitial Pneumonia in Systemic Sclerosis • >50% patients ↓(TLco)in early studies • Manoussakis et al. Chest 1987 • Steen et al. Arthritis Rheum 1985 • Since Rx for renal crisis, lung disease leading cause of death • Ferri et al Medicine (Baltimore) 2002 • Scussel-Lonzetti et al Medicine (Baltimore)2002 • Simeon et al Rheumatology.(Oxford) 2003 • More common in dcSSc • FA-SSc thought to be indistinguishable from CFA • Harrison et al. Am Rev Resp Dis 1991 • SSc ILD has a better prognosis than CFA • Wells et al. AJRCCM 1994

  18. Am J Respir Crit Care Med 2008

  19. Homogeneous Autoantibodies – Antinuclear Antibodies Centromeric Nucleolar • Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome • Tan et al. Arthritis Rheum 1980 • 95% SScHo & ReveilleArthritis Research & Therapy2003 • Auto antibodies • Anticentromere • Anti-topoisomerase 1 (Scl-70) • Anti RNA polymerase I & III

  20. Anticentromere Antibodies • Associated with CREST • Tan et al Arthritis Rheum 1980 • Riboldi et al Clinical and Experimental Rheumatology 1985 • Less likely than ACA neg to have pulmonary fibrosis • Steen et al Arthritis Rheum 1988 • Kane et al Respiratory Medicine 1996 • Defined by IIF pattern • Antigen not soluble • 6 defined antigens • ELISA available but not widely used

  21. Anti-topoisomerase 1 antibodies • 2/3 ATA dcSSc • Steen et al Arthritis Rheum 1988 • Associated with pulmonary fibrosis • Cassani et al Clin Exp Rheumatol 1987 • Manoussakis et al Chest 1987 • Steen et al Arthritis Rheum 1988

  22. Antibody characterisation • IIF pattern Anticentromere (ACA) • ENA Anti-topoisomerase 1(ATA) • Double immunodiffusion (Ouchterlony) • Counterimmunoelectrophoresis (CIE) • ELISA Anti-RNA polymerase I&III (ARA) • Immunoblot • Radiolabelled protein / RNA immunoprecipitation Th/To,others

  23. Immunoblotting Immunoprecipitation Cell lysate (radiolabelled) Cell lysate Precipitation of soluble antigens by patient serum SDS protein acrylamide gel electrophoresis Separated denatured proteins Precipitated native proteins SDS protein acrylamide gel electrophoresis Probing of denatured antigens by patient serum Detection of antigens by autoradiography Detection of antibodies with anti-human antibodies

  24. Radiolabelled protein immunoprecipitation patterns

  25. RNA immunoprecipitation

  26. Autoantibodies in Systemic Sclerosis • Anti-centromere: lcSSc and pulmonary hypertension • Anti-topoisomerase 1: dcSSc and interstitial pneumonia • Anti-RNA polymerase I & III: dcSSc, renal crisis, ‘watermelon stomach’ • Anti-PMScl: scleroderma/polymyositis overlap • Th/To: ‘scleroderma sine scleroderma’ • Anti-U3 RNP: dcSSc, African American ethnicity • Other SSc-associated AAs: U1-RNP, Ro, La etc

  27. Polymyositis/Dermatomyositis • Symmetrical proximal muscle weakness • Elevated serum muscle enzymes • EMG changes • Abnormal muscle biopsy • ± skin rash (Heliotrope rash, Gottron rash) • 4 criteria ‘definite’, 3 ‘probable’, 2 ‘possible’

  28. Autoantibodies in Idiopathic Inflammatory Myopathies – PM/DM • Jo-1: histidyl tRNA synthetase • 6 other tRNA synthetase antibodies • Anti-synthetase syndrome 20% IIM • High incidence interstitial pneumonia, • Arthritis, Raynaud’s, ‘mechanic’s hands’ • Mi-2: 5% IIM, predominantly DM, negative assoc IP • Anti-Signal recognition particle: bad myopathy • ‘Clinically amyopathic dermatomyositis’- CADM

  29. Median % 13 0 0 7 p<0.0001 Autoantibodies can predict likelihood of Intersitial Pneumonia in SSc

  30. Are Autoantibodies useful in Idiopathic Disease? • Useful in phenotyping connective tissue disease • ANAs occur in 37% ‘CFA’ (Turner-Warwick) • 22% my studied patients • CTD – associated AAs found in IPF cohorts • CTD-like symptoms common in idiopathic patients, biopsies NSIP > UIP

  31. Is it important? • CTD-associated ILD has better outcome • Immunosuppressants • ?Lesson from rheumatologists about ‘early synovitis’

  32. Coventry and Warwickshire ILD service • Established by David Parr/Christine O’Brien • Monthly multidisciplinary meeting • Thoracic surgeon present • Future developments • Bronchoalveolar lavage • Antinuclear antibody testing • Research/Trials • Specialist nurse

  33. Questions?

More Related